Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
US6762184B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 30, 2001 |
| Grant date | Jul 13, 2004 |
| Priority date | — |
| Expiry date | Apr 30, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D237/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This application relates to matrix metalloprotease inhibitors having the generalized formula in which r is 0-2, T is selected from and R40 is a mono-or bi-heterocyclic structure. More particularly, the present application claims the various stereoisomeric forms of 4-(4′-choloro-biphenyl-4-yl)-4-oxo-2-[2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)ethyl]butyric acid, as well as their pharmaceutically acceptable salts. Pharmaceutical compositions containing these compounds, and methods for inhibiting matrix metalloprotease activity in mammals such as humans and for treating various conditions by administering such compounds are also claimed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.